Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells

References

• Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al.. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 200315;21(18):3447–53.
   PubMed Web of Science ®Google Scholar
• Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness. J Hepatol. 2009;50(4):655–8.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Rickenbach M, Polesel J, Dal ML, Steffen I, Ledergerber B, et al.. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22(16):2135–41.
   PubMed Web of Science ®Google Scholar
• Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al.. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47(4):527–37.
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood. 2000;96(10):3553–9.
   PubMed Web of Science ®Google Scholar
• Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al.. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med. 2002;8(3):225–32.
   PubMed Web of Science ®Google Scholar
• Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MSJr, Weichold FF. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood. 2002;99(10):3771–9.
   PubMed Web of Science ®Google Scholar
• Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, et al.. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 2002;62(23):6901–8.
   PubMed Web of Science ®Google Scholar
• Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al.. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13(17):5183–94.
   PubMed Web of Science ®Google Scholar
• Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007;67(22):10920–8.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ikezoe T, Nishioka C, Bandobashi K, Takeuchi T, Adachi Y, et al.. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer. 2006;95(12):1653–62.
   PubMed Web of Science ®Google Scholar
• Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, et al.. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res. 2007;67(3):1221–7.
   PubMed Web of Science ®Google Scholar
• Chow WA, Guo S, Valdes-Albini F. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs. 2006;17(8):891–903.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, et al.. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20(16):2051–64.
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, et al.. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004;64(20):7426–31.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, et al.. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis. 1998;177(6):1533–40.
   PubMed Web of Science ®Google Scholar
• Aarnoutse RE, Droste JA, van Oosterhout JJ, Koopmans PP, Popescu M, Reiss P, et al.. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol. 2003;55(2):115–25.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al.. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2009;51(3):305–9.
   PubMed Web of Science ®Google Scholar
• Phenix BN, Angel JB, Mandy F, Kravcik S, Parato K, Chambers KA, et al.. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16(6):559–67.
   PubMed Web of Science ®Google Scholar
• Phenix BN, Cooper C, Owen C, Badley AD. Modulation of apoptosis by HIV protease inhibitors. Apoptosis. 2002;7(4):295–312.
   PubMed Web of Science ®Google Scholar
• Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, et al.. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15(15):1971–8.
   PubMed Web of Science ®Google Scholar
• Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med. 2004;164(21):2349–54.
   PubMedGoogle Scholar
• McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24(31):5005–9.
   PubMed Web of Science ®Google Scholar